Hepatitis B during or after cancer chemotherapy is one of the most serious complication in hepatitis B virus (HBV) carriers [1] [2] [3] [4] [5] . In an epidemiological study [6] , hepatitis B developed with high frequency and hepatitis often resulted in fatal hepatic failure. We conducted a clinical trial of interferon-alpha (INF-a) administration concurrently with intensive chemotherapy for malignant lymphoma (ML).
Between April, 1992 and March, 1997, consecutive 7 HBV carriers with ML were treated with IFN-a and intensive chemotherapy (Table 1 ). All but one patient (patient 5) were in the state of seroconversion; negative for HBe-antigen and positive for antibody to HBe-antigen. In the six seroconverted patients, serum aminotransferase levels were almost within the normal range at the start of treatment. HBV-DNA polymerase activity were in the normal range as well. Patient 5, a 25-year-old man, had not shown seroconversion. The HBV-DNA polymerase activity was high (3,544 cpm) at the start of chemotherapy.
The chemotherapy regimens used for ML included the first-generation and third-generation chemotherapies; CHOP therapy for four patients, biweekly CHOP therapy for one, VACOP-B therapy for one, CHOP-MEVP sequential therapy for one. Corticosteroids were eliminated from each regimen. Six mega-units of IFN-a (Sumiferon; Sumitomo Pharmaceuticals Ltd.) was administered concurrently with the treatment cycle; IFN-a was given twice a week in four patients, three times a week in two. In one patient (patient 3) who was treated with CHOP-MEVP sequential therapy, IFN-a was administered for nine consecutive days after each treatment cycle. HBV-DNA polymerase activity was measured by radioassay at the start of chemotherapy, every other week during treatment, and two weeks after the completion of treatment. Adverse effects were recorded according to WHO criteria.
There were no patients in whom hepatitis developed (Table 1 ). In the six seroconverted patients, the serum aminotransferase levels and HBV-DNA polymerase activity remained almost within the normal range throughout the courses of chemotherapy. The adverse effects due to IFN-a and intensive chemotherapy were mild and reversible; low-grade fever was seen in three patients, anorexia in two, grade 3-4 leukopenia in four, and mild hyperglycemia in one. The chemotherapy schedule was delayed by seven days in only one patient (patient 2). In patient 5, IFN-a was administered at a dose of six megaunits twice per week. The HBV-DNA polymerase activity was high (3,544 cpm) at the start of chemotherapy, and gradually decreased to the normal range. Hepatitis did not developed during tretment, but transient elevation of surum aminotransferase and HBV-DNA polymerase activity were observed afterwards.
In all of the patients, complete remission (CR) of ML was attained. As of the end of September 1997, four patients showed sustained CR for 37-45 months. In one patient (patient 7), ML relapsed in the brain. Two patients died of unrelated causes with ML or treatment, suicide and pre-existing gallbladder cancer, respectively. No signs of hepatitis have been observed in all of the seven patients.
In the survey of 1,380 patients undergoing chemotherapy for ML collected from eight institutions in Japan, 45 patients (3.26%) were HBV carriers. Of these, the reactivation of HBV infection and the consequent hepatitis was observed as many as 17 patients (37.8%), and seven patients (15.6%) succumbed to a hepatic failure [6] . Mechanism of the hepatitis development after chemotherapy is most likely that HBV replication occurs during the immunosuppressive therapy and massive destruction of HBV-infected hepatocytes follows after the recovery of host immunity. Modern intensive chemotherapy for hematologic and other malignancies is well known to be highly immunosuppressive. Dose intensity reflected the frequency and severity of hepatitis; hepatitis developed in 25% of the patients treated with first generation chemotherapy vs. 63.2% of third generation chemotherapy [6] . Once hepatitis developed, motality rate is very high. Therefore, it is important to prevent hepatitis development by means of inhibiting HBV replication during immunosuppressive therapy. This clinical trial demonstrated that IFN-a can inhibit HBV replication and prevent the hepatitis development.
In recent years, the chemotherapy for hematologic and other malignancies has become more agressive and more Abbreviations: DSC -diffuse small cleaved; FL -follicular large; DMix -diffuse mixed; DL -diffuse large; eAg/eAb -HBe-antigen/antibody to HBe-antigen; DNA-P -HBV-DNA polymerase activity, value at the start of chemotherapy/highest value in the course of treatment/value at the end of treatment; CTX -chemotherapy; CHOP -cyclophosphamide, doxorubicin, vincristine: MEVP -mitoxantrone, etoposide, vindesine; VACOP-B -etoposide, doxorubicin, cyclophosphamide, vincristine, bleomycin; ALT -alanine aminotransferase.
immunosuppressive. The risk of severe hepatitis due to chemotherapy also has been increasing. Although further study in a greater number of patients is required, the administration of interferon is recommended in all HBV carriers who receive intensive chemotherapy.
Frey's syndrome after cisplatin-based chemotherapy for testicular teratoma
Frey's syndrome is a rare condition which is characterised by gustatory sweating. We describe a case of Frey's syndrome in a young man treated with cisplatin based therapy for testicular teratoma.
A 22-year-old man first presented in May 1990 with a threeweek history of a swollen left testicle associated with pain in his left iliac fossa. He underwent a left orchidectomy and the pathology showed a malignant teratoma intermediate with seminomatous elements, yolk sac differentiation, some syncytiotrophoblastic elements and local lympho-vascular invasion. His bHCG after surgery did not return to normal and a CT scan of his abdomen showed a 1 cm node below the left renal vein. He was treated with four cycles of BEP (bleomycin, etoposide cisplatin) chemotherapy and achieved a complete response.
He represented in May 1992, with an elevated bHCG (848U/1) and a CT scan of his abdomen identified a 3 cm mass in the left para aortic region. He was treated with weekly BOP (bleomycin, vincristine, cisplatin) for six weeks, followed by two cycles of IPE (ifosfamide, etoposide, cisplatin). He proceeded to surgery in October 1992 where a 4 cm mass was resected from below the left renal artery which revealed differentiated teratoma.
Post operatively he made a good recovery and subsequent follow-up has revealed no evidence of recurrent disease although there was evidence of a peripheral neuropathy and hearing loss consistent with cisplatin exposure.
In September 1993, he started experiencing gustatory sweating after spicy foods. The sweating was confined to the face on both sides running into the scalp, attacks would last between 10 minutes to one hour and would subside spontaneously. These attacks became more frequent over the next three years. He was admitted to hospital in June 1996 for observation of the attacks. Investigations at this time were normal and during an attack there was no evidence of hypotension or bradycardia. A clinical was diagnosis of bilateral Frey's syndrome was made.
He was commenced on a topical glycopyrrolate cream (1%) applied to his face initially every three days. Subsequently, the strength was increased to 2% and the frequency of application reduced to every two weeks although during summer he required application two to three times per week to control the symptoms. With this regimen of treatment his sweats had decreased by approximately 60%-70%.
Frey's syndrome is characterised by localised sweating and flushing during mastication and is a common sequelae of parotid surgery [1] . The mechanism is thought to be the aberrant regrowth of post ganglionic parasympathetic fibres from the otic ganglion. Following damage, these fibres regenerate and connect with sweat glands in the skin. Other causes include post herpes infection, condylar fractures, and dental surgery [3] [4] [5] . The main method of diagnosis is clinical but the minor starch iodine test and a biosensor can localise the affected area. Treatment is either surgical, application of topical anticholinergics, systemic anticholinergics, topical application of aluminum chloride or localised injection of botulinum toxin [1, 7] . The most common treatment is the application of topical anticholinergics -glycopyrrolate or diphemanil methylsulphate which will partially or completely control the symptoms in 50%-80% of cases [1, 6] .
Neurotoxicity is common after cisplatin chemotherapy especially after cumulative doses greater than 300 mg/m 2 [8] which is usually manifest as a peripheral neuropathy or ototoxicity. This patient had a cumulative dose of 680 mg/m 2 of cisplatin and had evidence of a peripheral neurotoxicity. This is the first case described to our knowledge of bilateral Frey's syndrome in a patient treated with cisplatin based chemotherapy. Other chemotherapy agents used in his treatment (vincristine, ifosfamide, etoposide, bleomycin) may have contributed to the development of the syndrome. 
